Sugi Predict
/ Targets
/ MLX
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to MLX by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| LMX-4 for Postoperative Pain Management in Infants and Children Undergoing Penoplasty Surgery |
PHASE4 | COMPLETED |
| A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia |
PHASE3 | COMPLETED |
| TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis |
PHASE3 | COMPLETED |
| Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors |
PHASE2 | UNKNOWN |
| A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis |
PHASE2 | COMPLETED |
| Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer |
PHASE1/PHASE2 | SUSPENDED |
| A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) |
PHASE2 | RECRUITING |
| Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer |
PHASE1/PHASE2 | WITHDRAWN |
| A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy |
PHASE2 | RECRUITING |
| Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor |
PHASE1 | COMPLETED |
| Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 |
PHASE1 | COMPLETED |
| Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS |
PHASE1 | UNKNOWN |
| Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) |
nan | WITHDRAWN |
| Autophagy in Systemic Lupus Erythematosus |
nan | UNKNOWN |
| X-chromosome Inactivation, Epigenetics and the Transcriptome |
nan | COMPLETED |
| Study of the Sex Differences in Inflammatory Diseases in Children |
nan | UNKNOWN |
| A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia |
nan | COMPLETED |
| Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic |
nan | COMPLETED |
| Study of Selected X-Linked Disorders: Aicardi Syndrome |
nan | RECRUITING |
| Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing |
nan | RECRUITING |
| Gene x Behavior Interaction in the Look AHEAD Study |
nan | COMPLETED |
| Amyotrophic Lateral Sclerosis (ALS) Families Project |
nan | RECRUITING |
| Epidemiology of Atherosclerosis |
nan | COMPLETED |
| Patient-derived Glioma Stem Cell Organoids |
nan | ACTIVE_NOT_RECRUITING |
| Studying Chromosomes in Samples From Younger Patients With Neuroblastoma |
nan | COMPLETED |
| Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives |
nan | UNKNOWN |
| Correlation Between PT and INR to Factor 7 |
nan | UNKNOWN |
| The Effect of PPI Therapy on Weight, Gut Microbiome, and Expression of GPR41 and GPR43 |
nan | UNKNOWN |
| Improvements in Aerobic Fitness With Exercise Training: the Role of Myokines |
nan | COMPLETED |
| Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate? |
nan | RECRUITING |
Related proteins — ESM-2 sequence neighbours (a MLX binder may also engage these)